Healthmine‘s Executive Vice President of Consulting & Professional Services Melissa Smith shared six takeaways from the 2023 Medicare Advantage and Part D Final Rule. Learn how to successfully navigate the regulatory updates by clicking here.
Capable Health has raised $6 million in seed funding led by M13, with participation from AlleyCorp and Able Partners. The health tech startup’s software platform enables providers to launch and scale their own HIPAA-compliant digital clinics with 80 percent less cost and time than it currently takes.
Capable’s platform guides patients through onboarding and sign up, deliver personalized care plans to keep patients on track with their health goals, and connects patients and providers directly through messaging and video chat.
To read more, click here.
Imagene AI, a company developing AI-based precision medicine for cancer, has raised $21.5 million in a series of funding rounds. It raised $3 million in seed funding led by Blumberg Capital and an $18.5 million Series A round led by technology-driven cancer medicine investors Larry Ellison, Dr. David Agus, and AI imaging space pioneer Eyal Gura.
Using digitized biopsy images, Imagene’s AI diagnostic technology does molecular analysis in real time as part of its goal to set a new standard for the level of accuracy and reducing the time required for results, from several weeks to a couple of minutes.
Imagene’s technology classifies patterns that cannot be seen by the human eye, evolving genomics, proteomics, and spatial insights to better understand the recurrence of specific cancers and their resistance mechanisms. The idea is for its technology to enable better stratification of patients in clinical trials and the discovery of novel targets for new drugs.
To read more, click here.
A blog post explores the trend of health tech startups taking on risk, in part because of public health policy driving investment in these companies.
“Over the last decade, value-based care has been partially implemented by healthcare executives and furthered by policy. But we’re seeing more and more health tech startups pitch taking on risk. Their care models offer the promise of providing more frequent care that better meets patient needs and helps them better manage their conditions.”
Jacob Effron’s deep dive on this topic on the Vital Signs blog can be found here. (Hat tip to Health Tech Nerds)
PolyCore Therapeutics, Inc., a biopharmaceutical company developing treatments for patients suffering from dyskinesia and cognitive impairment associated with neurodegenerative disorders, announced a seed investment from Xontogeny, LLC and Ben Franklin Technology Partners of Southeastern Pennsylvania to advance their lead compound, PCT-3012, a novel G protein-biased D3 receptor agonist to reduce motor impairment in Parkinson’s Disease, through IND-enabling work.
Picture: akindo, Getty Images
